Germline Two-Hit Tumor Predisposition Module

Oncology Module germline_two_hit_tumor_predisposition 22 disorders Pathograph 6

A conserved mechanism module for the Knudson two-hit route by which a constitutional (germline) tumor-suppressor lesion produces Mendelian cancer predisposition. The chain runs from a heterozygous germline loss-of-function first hit carried by every somatic cell, through somatic inactivation of the remaining wild-type allele (the rate-limiting second hit, most often loss of heterozygosity via mitotic recombination, chromosome nondisjunction, deletion, intragenic mutation, or promoter hypermethylation), to biallelic tumor suppressor loss in a susceptible cell, clonal expansion and tumor initiation, and finally the characteristic epidemiology of hereditary cancer: earlier onset, multifocality, bilaterality in paired organs, and a gene-specific tumor spectrum. This is deliberately the *predisposition* arm and not a restatement of the somatic hallmark modules. evading_growth_suppressors models the tumor-cell-intrinsic consequence of having lost an RB- or p53-axis brake; genome_instability_mutation models the mutator engine; dna_repair_synthetic_lethality models the therapeutic vulnerability created by biallelic loss of homologous recombination. This module models the population-genetic and allelic architecture that explains why a carrier of one damaged allele develops tumors at all, why they develop them early and in multiples, and why the tumor spectrum is narrower than the constitutional genotype would predict. A conforming disorder therefore typically declares conformance BOTH here and to whichever downstream hallmark module its specific tumor suppressor feeds.

⚙

Pathophysiology Nodes

5 shared nodes are defined in this module.

◉

Cell Types

No cell types are annotated for this module.

⇄

Biological Processes

negative regulation of cell population proliferation GO:0008285 DECREASED mitotic recombination GO:0006312 INCREASED negative regulation of cell population proliferation GO:0008285 LOSS OF FUNCTION cell population proliferation GO:0008283 INCREASED

Notes

This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g. "germline_two_hit_tumor_predisposition#Biallelic Tumor Suppressor Inactivation in a Susceptible Cell"). Key gene-specific substitutions conforming entries make at the first-hit node: RB1 (retinoblastoma), TP53 (Li-Fraumeni), APC (familial adenomatous polyposis), the mismatch-repair genes MLH1/MSH2/MSH6/ PMS2 (Lynch syndrome), BRCA1/BRCA2 (hereditary breast and ovarian cancer), VHL (von Hippel-Lindau), NF1/NF2, PTEN (PTEN hamartoma tumor syndrome), STK11 (Peutz-Jeghers), SMAD4/BMPR1A (juvenile polyposis), CDH1 (hereditary diffuse gastric cancer), CDKN2A (familial melanoma), FLCN (Birt-Hogg-Dube), FH (hereditary leiomyomatosis and renal cell cancer), the succinate dehydrogenase subunits SDHA/SDHB/SDHC/SDHD (hereditary paraganglioma-pheochromocytoma), MEN1, PRKAR1A (Carney complex), SMARCB1 (rhabdoid tumor predisposition), and DICER1. Two things a conformer must NOT copy uncritically. (1) The module is scoped to *tumor suppressors*: the dominantly acting proto-oncogene predisposition syndromes, where a germline activating variant needs no second hit at the same locus, are out of scope at the second-hit and biallelic nodes — RET in multiple endocrine neoplasia type 2 and MET in hereditary papillary renal carcinoma are the canonical counterexamples, and an entry for those should conform (if at all) only at the constitutional-first-lesion and tumor-spectrum nodes with the gain-of-function route stated explicitly. (2) Strict biallelic inactivation is not universal even among tumor suppressors; the curated continuum_haploinsufficiency hypothesis records that partial dosage loss can suffice, so a conformer that lacks demonstrated second-hit or LOH evidence in its own tumor tissue should say so rather than asserting the second hit by analogy. The aspirin chemoprevention treatment pattern below is evidenced only in Lynch syndrome carriers and is NOT inherited as a treatment recommendation by conforming disorders. Key conformance target (rate-limiting node): "germline_two_hit_tumor_ predisposition#Biallelic Tumor Suppressor Inactivation in a Susceptible Cell".

Mechanistic Hypotheses

Classical Knudson Two-Hit (Complete Biallelic Inactivation) Model

classical_two_hit CANONICAL Evidence: 1

Evidence balance 1 support

Tumorigenesis in a predisposition carrier requires complete functional loss of both alleles: the inherited first hit plus a somatic second hit at the same locus. Under this reading a heterozygous cell is functionally normal, the second hit is the rate-limiting event, and demonstrating loss of heterozygosity or a somatic second mutation in tumor tissue is the confirmatory finding.

Continuum Model — Partial Tumor Suppressor Inactivation Suffices

continuum_haploinsufficiency ALTERNATIVE Evidence: 1

Evidence balance 1 support

Complete biallelic loss is one end of a continuum rather than a threshold. Partial inactivation — haploinsufficiency, hypomorphic alleles, dosage reduction, or transcriptional downregulation of the retained allele — can itself contribute critically to tumorigenesis, so a tumor without demonstrable loss of heterozygosity is not thereby excluded from being driven by the inherited lesion. This matters for curation: absence of a documented second hit is evidence about the mechanism, not a licence to assert one by analogy with retinoblastoma.

Discussions and Knowledge Gaps

Why does a tumor-suppressor lesion carried in every cell of the body produce a narrow, gene-specific tumor spectrum rather than a generalized excess of cancer across all tissues?

KNOWLEDGE GAP OPEN gap_tissue_selectivity_of_predisposition

Attached to: Biallelic Tumor Suppressor Inactivation in a Susceptible Cell Early-Onset, Multifocal, and Bilateral Tumor Spectrum

The two-hit model explains the *rate* of tumor formation in a carrier but not its *location*. RB1 carriers develop retinoblastoma and osteosarcoma, not carcinoma of every epithelium; VHL carriers develop hemangioblastoma and clear-cell renal carcinoma; BRCA1 carriers develop breast and ovarian rather than pan-tissue cancer — despite the constitutional lesion being uniformly distributed and the second hit being, on the face of it, equally available everywhere. Candidate explanations include tissue-specific dependence on the gene's function, differences in the size and turnover of the at-risk progenitor pool, tissue-specific rates of the particular mutational mechanism that produces the second hit, and lineage-specific requirements for cooperating events. This is deliberately recorded as an open gap so that conforming entries state their tumor spectrum as an observation rather than deriving it from the module, which cannot predict it.

Proposed experiments: Lineage-resolved second-hit rate measurement in carrier tissue

↗

Used By Disorder Entries

Birt-Hogg-Dube Syndrome via Germline FLCN First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic FLCN Second-Hit Inactivation → Somatic Second-Hit Inactivation of the Wild-Type Allele , Folliculin Loss and FNIP1-AMPK-mTOR Nutrient Sensing Dysregulation → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Multiorgan Hamartoma and Renal Tumor Development → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Carney Complex via Germline PRKAR1A First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic PRKAR1A Second-Hit Loss of Heterozygosity → Somatic Second-Hit Inactivation of the Wild-Type Allele , Loss of RIalpha Restraint on cAMP-Stimulated PKA Signaling → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Multiple Neoplasia and Paradoxical Endocrine Overactivity → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

CDH1-Related Hereditary Diffuse Gastric Cancer via Germline CDH1 First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Biallelic E-Cadherin Loss in Gastric Epithelium → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Diffusely Infiltrative Signet-Ring Cell Carcinoma → Clonal Expansion and Tumor Initiation , Diffuse Gastric and Lobular Breast Cancer Risk → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Classic Familial Adenomatous Polyposis via Germline APC loss-of-function predisposition → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic APC Second-Hit Inactivation (Knudson Two-Hit) → Somatic Second-Hit Inactivation of the Wild-Type Allele , Adenoma initiation → Clonal Expansion and Tumor Initiation

Cowden Syndrome via PTEN Loss and PI3K/AKT/mTOR Pathway Activation → Constitutional First-Hit Tumor Suppressor Inactivation , Increased Cancer Risk → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

DICER1 Tumor Predisposition Syndrome via Germline DICER1 First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Pleiotropic Childhood-Onset Neoplasm Spectrum → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Familial Adenomatous Polyposis via APC Tumor Suppressor Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Adenoma Formation → Clonal Expansion and Tumor Initiation

Gorlin Syndrome via PTCH1 Somatic Second-Hit Loss → Somatic Second-Hit Inactivation of the Wild-Type Allele

Hereditary Breast and Ovarian Cancer Syndrome via BRCA1/2 Tumor Suppressor Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Tumor Development → Clonal Expansion and Tumor Initiation

Hereditary Leiomyomatosis and Renal Cell Cancer via Germline FH First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic FH Second-Hit Inactivation and Biallelic Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Leiomyomatosis and Aggressive Renal Cell Carcinoma → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Hereditary Pheochromocytoma-Paraganglioma Syndrome via Germline SDHx First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Biallelic SDHx Loss and Succinate Dehydrogenase Deficiency → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Paraganglioma and Pheochromocytoma Development → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Juvenile Polyposis Syndrome via Germline BMPR1A loss-of-function predisposition → Constitutional First-Hit Tumor Suppressor Inactivation , Germline SMAD4 loss-of-function predisposition → Constitutional First-Hit Tumor Suppressor Inactivation

Li-Fraumeni Syndrome via Germline TP53 Heterozygosity → Constitutional First-Hit Tumor Suppressor Inactivation , Loss of Heterozygosity (Second Hit) → Somatic Second-Hit Inactivation of the Wild-Type Allele , TP53 Tumor Suppressor Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Tumor Development → Clonal Expansion and Tumor Initiation

Lynch Syndrome via Accelerated Tumor Development → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Multiple Endocrine Neoplasia Type 1 via Germline MEN1 First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic MEN1 Second-Hit Inactivation → Somatic Second-Hit Inactivation of the Wild-Type Allele , Biallelic Menin Loss in Endocrine Tissue → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Multicentric Endocrine Tumorigenesis → Clonal Expansion and Tumor Initiation , MEN1 Tumor Spectrum and Reduced Life Expectancy → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Neurofibromatosis Type 1 via NF1 Tumor Suppressor Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell

Peutz-Jeghers syndrome via STK11 germline loss-of-function → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic STK11 second-hit and malignant transformation → Somatic Second-Hit Inactivation of the Wild-Type Allele

Pheochromocytoma and Paraganglioma via Somatic Loss of Maternal Chromosome 11 → Somatic Second-Hit Inactivation of the Wild-Type Allele

PTEN Hamartoma Tumor Syndrome via PTEN loss and PI3K AKT mTOR activation → Constitutional First-Hit Tumor Suppressor Inactivation , Multiorgan cancer predisposition → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

Retinoblastoma via Germline RB1 First-Hit Inactivation → Constitutional First-Hit Tumor Suppressor Inactivation , Somatic RB1 Second-Hit Inactivation → Somatic Second-Hit Inactivation of the Wild-Type Allele

Schwannomatosis via Germline SMARCB1 or LZTR1 Loss of Function (First Hit) → Constitutional First-Hit Tumor Suppressor Inactivation , Composite 4-Hit/3-Event 22q Inactivation → Somatic Second-Hit Inactivation of the Wild-Type Allele

Von Hippel-Lindau Disease via VHL Tumor Suppressor Loss → Biallelic Tumor Suppressor Inactivation in a Susceptible Cell , Tumor Development → Early-Onset, Multifocal, and Bilateral Tumor Spectrum

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence-backed metadata.

⚙

Pathophysiology

Constitutional First-Hit Tumor Suppressor Inactivation

trigger

A heterozygous loss-of-function alteration in a tumor-suppressor gene is present in the germline and therefore in every somatic cell of the carrier. The alteration itself is recessive at the cellular level — one functional allele generally suffices for normal tissue function — which is why the trait segregates as an autosomal dominant *predisposition* while the cellular lesion behaves recessively. Its effect is to convert a two-mutation requirement into a one-mutation requirement in every cell of the at-risk tissue simultaneously.

negative regulation of cell population proliferation GO:0008285 DECREASED

Used by disorders

Birt-Hogg-Dube Syndrome as Germline FLCN First-Hit Inactivation

Carney Complex as Germline PRKAR1A First-Hit Inactivation

CDH1-Related Hereditary Diffuse Gastric Cancer as Germline CDH1 First-Hit Inactivation

Classic Familial Adenomatous Polyposis as Germline APC loss-of-function predisposition

Cowden Syndrome as PTEN Loss and PI3K/AKT/mTOR Pathway Activation

DICER1 Tumor Predisposition Syndrome as Germline DICER1 First-Hit Inactivation

Hereditary Leiomyomatosis and Renal Cell Cancer as Germline FH First-Hit Inactivation

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Germline SDHx First-Hit Inactivation

Juvenile Polyposis Syndrome as Germline BMPR1A loss-of-function predisposition

Juvenile Polyposis Syndrome as Germline SMAD4 loss-of-function predisposition

Li-Fraumeni Syndrome as Germline TP53 Heterozygosity

Multiple Endocrine Neoplasia Type 1 as Germline MEN1 First-Hit Inactivation

Peutz-Jeghers syndrome as STK11 germline loss-of-function

PTEN Hamartoma Tumor Syndrome as PTEN loss and PI3K AKT mTOR activation

Retinoblastoma as Germline RB1 First-Hit Inactivation

Schwannomatosis as Germline SMARCB1 or LZTR1 Loss of Function (First Hit)

Downstream

Somatic Second-Hit Inactivation of the Wild-Type Allele Because the constitutional lesion is already present in every cell, only one further somatic event at the same locus is needed to complete inactivation, and that event becomes the rate-limiting step.

Somatic Second-Hit Inactivation of the Wild-Type Allele

amplifier

A somatic event inactivates the remaining wild-type allele in a single cell of the at-risk tissue. The dominant route is loss of heterozygosity, which Cavenee and colleagues showed arises by chromosome-level mechanisms — mitotic nondisjunction losing the homologous wild-type chromosome, or mitotic recombination replacing the wild-type region with a copy of the mutant one. Interstitial deletion, an independent intragenic point mutation, and promoter hypermethylation (an epigenetic second hit) are the other recognized routes. This node is where the disorder-specific tumor tissue first diverges from the carrier's constitutional genotype.

mitotic recombination GO:0006312 INCREASED

Used by disorders

Birt-Hogg-Dube Syndrome as Somatic FLCN Second-Hit Inactivation

Carney Complex as Somatic PRKAR1A Second-Hit Loss of Heterozygosity

Classic Familial Adenomatous Polyposis as Somatic APC Second-Hit Inactivation (Knudson Two-Hit)

Gorlin Syndrome as PTCH1 Somatic Second-Hit Loss

Li-Fraumeni Syndrome as Loss of Heterozygosity (Second Hit)

Multiple Endocrine Neoplasia Type 1 as Somatic MEN1 Second-Hit Inactivation

Peutz-Jeghers syndrome as Somatic STK11 second-hit and malignant transformation

Pheochromocytoma and Paraganglioma as Somatic Loss of Maternal Chromosome 11

Retinoblastoma as Somatic RB1 Second-Hit Inactivation

Schwannomatosis as Composite 4-Hit/3-Event 22q Inactivation

Downstream

Biallelic Tumor Suppressor Inactivation in a Susceptible Cell Completion of the second hit leaves the affected cell with no functional copy of the tumor suppressor.

Biallelic Tumor Suppressor Inactivation in a Susceptible Cell

central effector

The rate-limiting, disorder-agnostic state this module exists to name: a single cell within a competent tissue now carries no functional copy of the tumor suppressor, having combined the inherited and the acquired lesion. Pan-cancer germline-plus-tumor sequencing confirms this is the general rule and not a retinoblastoma peculiarity — germline tumor-suppressor variant carriers show frequent loss of heterozygosity or biallelic two-hit events in their tumors, together with reduced expression of the affected gene. This is the node conforming disorder entries should attach to when they have demonstrated biallelic loss in their own tumor tissue.

negative regulation of cell population proliferation GO:0008285 LOSS OF FUNCTION

Used by disorders

Birt-Hogg-Dube Syndrome as Folliculin Loss and FNIP1-AMPK-mTOR Nutrient Sensing Dysregulation

Carney Complex as Loss of RIalpha Restraint on cAMP-Stimulated PKA Signaling

CDH1-Related Hereditary Diffuse Gastric Cancer as Biallelic E-Cadherin Loss in Gastric Epithelium

Familial Adenomatous Polyposis as APC Tumor Suppressor Loss

Hereditary Breast and Ovarian Cancer Syndrome as BRCA1/2 Tumor Suppressor Loss

Hereditary Leiomyomatosis and Renal Cell Cancer as Somatic FH Second-Hit Inactivation and Biallelic Loss

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Biallelic SDHx Loss and Succinate Dehydrogenase Deficiency

Li-Fraumeni Syndrome as TP53 Tumor Suppressor Loss

Multiple Endocrine Neoplasia Type 1 as Biallelic Menin Loss in Endocrine Tissue

Neurofibromatosis Type 1 as NF1 Tumor Suppressor Loss

Von Hippel-Lindau Disease as VHL Tumor Suppressor Loss

Downstream

Clonal Expansion and Tumor Initiation Complete loss of the suppressor's restraining function gives the affected cell a selective growth advantage over its neighbours.

Clonal Expansion and Tumor Initiation

effector

The cell that has lost both alleles escapes the antiproliferative or genome-protective program the gene enforced, gains a selective advantage over surrounding wild-type tissue, and expands clonally to initiate a neoplasm. Only a small number of events acting on cell birth and death processes are needed to reach this point, which is why hereditary tumors can arise so early. What the escape consists of is gene-specific and is modeled by the downstream hallmark modules rather than re-derived here.

cell population proliferation GO:0008283 INCREASED

Used by disorders

CDH1-Related Hereditary Diffuse Gastric Cancer as Diffusely Infiltrative Signet-Ring Cell Carcinoma

Classic Familial Adenomatous Polyposis as Adenoma initiation

Familial Adenomatous Polyposis as Adenoma Formation

Hereditary Breast and Ovarian Cancer Syndrome as Tumor Development

Li-Fraumeni Syndrome as Tumor Development

Multiple Endocrine Neoplasia Type 1 as Multicentric Endocrine Tumorigenesis

Downstream

Early-Onset, Multifocal, and Bilateral Tumor Spectrum Because every cell of the at-risk tissue is one event away from the biallelic state, initiation events occur independently and repeatedly within a carrier.

Early-Onset, Multifocal, and Bilateral Tumor Spectrum

consequence

The clinical signature of the module and the basis on which hereditary predisposition is recognized before any gene is sequenced: tumors arise earlier than their sporadic counterparts, at multiple independent foci, and bilaterally in paired organs, because independent second hits occur independently across a whole tissue of already-primed cells. Knudson derived the same Poisson structure that explains bilateral and multifocal disease also explains incomplete penetrance — the carrier who develops no tumor is the tail of the same distribution, not a separate phenomenon. The tumor spectrum is nevertheless gene-specific and far narrower than the constitutional genotype alone would predict, which is recorded as an open knowledge gap below.

Used by disorders

Birt-Hogg-Dube Syndrome as Multiorgan Hamartoma and Renal Tumor Development

Carney Complex as Multiple Neoplasia and Paradoxical Endocrine Overactivity

CDH1-Related Hereditary Diffuse Gastric Cancer as Diffuse Gastric and Lobular Breast Cancer Risk

Cowden Syndrome as Increased Cancer Risk

DICER1 Tumor Predisposition Syndrome as Pleiotropic Childhood-Onset Neoplasm Spectrum

Hereditary Leiomyomatosis and Renal Cell Cancer as Leiomyomatosis and Aggressive Renal Cell Carcinoma

Hereditary Pheochromocytoma-Paraganglioma Syndrome as Paraganglioma and Pheochromocytoma Development

Lynch Syndrome as Accelerated Tumor Development

Multiple Endocrine Neoplasia Type 1 as MEN1 Tumor Spectrum and Reduced Life Expectancy

PTEN Hamartoma Tumor Syndrome as Multiorgan cancer predisposition

Von Hippel-Lindau Disease as Tumor Development